CN107335055B - 一种兽用中药免疫增强剂及其应用 - Google Patents
一种兽用中药免疫增强剂及其应用 Download PDFInfo
- Publication number
- CN107335055B CN107335055B CN201710598649.1A CN201710598649A CN107335055B CN 107335055 B CN107335055 B CN 107335055B CN 201710598649 A CN201710598649 A CN 201710598649A CN 107335055 B CN107335055 B CN 107335055B
- Authority
- CN
- China
- Prior art keywords
- parts
- polysaccharide
- chinese medicine
- traditional chinese
- veterinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 230000000091 immunopotentiator Effects 0.000 title claims abstract description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 132
- 150000004676 glycans Chemical class 0.000 claims abstract description 61
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 60
- 239000005017 polysaccharide Substances 0.000 claims abstract description 60
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229920001491 Lentinan Polymers 0.000 claims abstract description 44
- 229940006091 aloe polysaccharide Drugs 0.000 claims abstract description 44
- 229940115286 lentinan Drugs 0.000 claims abstract description 44
- 208000010359 Newcastle Disease Diseases 0.000 claims abstract description 42
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 42
- 239000004359 castor oil Substances 0.000 claims abstract description 42
- 235000019438 castor oil Nutrition 0.000 claims abstract description 42
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 42
- -1 polyoxyethylene Polymers 0.000 claims abstract description 42
- 239000008215 water for injection Substances 0.000 claims abstract description 39
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 37
- 239000002994 raw material Substances 0.000 claims abstract description 34
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 15
- 102000036639 antigens Human genes 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 244000061520 Angelica archangelica Species 0.000 claims abstract 3
- 239000011259 mixed solution Substances 0.000 claims description 16
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 230000002434 immunopotentiative effect Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 241000125175 Angelica Species 0.000 description 44
- 210000000952 spleen Anatomy 0.000 description 23
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 229960004397 cyclophosphamide Drugs 0.000 description 15
- 238000002156 mixing Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 210000001541 thymus gland Anatomy 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 244000144972 livestock Species 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010003694 Atrophy Diseases 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000037444 atrophy Effects 0.000 description 6
- 239000004064 cosurfactant Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 241001116389 Aloe Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- ITYXXSSJBOAGAR-UHFFFAOYSA-N 1-(methylamino)-4-(4-methylanilino)anthracene-9,10-dione Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(NC)=CC=C1NC1=CC=C(C)C=C1 ITYXXSSJBOAGAR-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000222418 Lentinus Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940099373 sudan iii Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
因素水平 | 当归多糖 | 香菇多糖 | 芦荟多糖 |
1 | 5 | 2 | 4 |
2 | 10 | 4 | 8 |
3 | 15 | 6 | 12 |
脾脏指数 | 胸腺指数 | 增殖刺激指数 | |
1 | 4.04±0.71* | 1.70±0.57* | 2.65±0.54# |
2 | 3.72±1.31 | 1.88±0.42* | 2.92±0.51# |
3 | 4.89±1.54*# | 1.88±0.43* | 2.19±0.35# |
4 | 3.08±0.92 | 1.91±0.21* | 1.79±0.68* |
5 | 3.18±0.82 | 1.80±0.36* | 2.68±1.11# |
6 | 4.26±1.07* | 2.07±0.39 | 2.73±0.39# |
7 | 3.98±1.23* | 1.96±0.11 | 2.07±0.75# |
8 | 3.27±1.16 | 2.24±0.22 | 1.81±0.34* |
9 | 4.04±1.04* | 1.99±0.76 | 2.23±0.23# |
正常组 | 2.79±0.40 | 2.34±0.38# | 2.60±0.18# |
环磷酰胺组 | 3.76±0.96 | 1.87±0.18* | 1.35±0.13* |
组别 | 14天 | 21天 | 28天 | 35天 |
生理盐水组 | 3 | 3 | 3 | 3 |
鸡新城疫灭活抗原组 | 5 | 6 | 6 | 5 |
中药增强剂组 | 3 | 3 | 3 | 3 |
中药增强剂+灭活抗原组 | 6 | 9 | 11 | 11 |
鸡新城疫疫灭活苗(La Sota株)组 | 6 | 8 | 9 | 9 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710598649.1A CN107335055B (zh) | 2017-07-21 | 2017-07-21 | 一种兽用中药免疫增强剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710598649.1A CN107335055B (zh) | 2017-07-21 | 2017-07-21 | 一种兽用中药免疫增强剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107335055A CN107335055A (zh) | 2017-11-10 |
CN107335055B true CN107335055B (zh) | 2020-05-01 |
Family
ID=60217374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710598649.1A Active CN107335055B (zh) | 2017-07-21 | 2017-07-21 | 一种兽用中药免疫增强剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107335055B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101690809A (zh) * | 2009-09-30 | 2010-04-07 | 西北农林科技大学 | 一种蜂胶与黄芪多糖复方纳米乳佐剂及其制备方法和应用 |
CN102524589A (zh) * | 2012-02-13 | 2012-07-04 | 天津市畜牧兽医研究所 | 一种断奶仔猪饲料及其制备方法与应用 |
CN103463634A (zh) * | 2013-09-09 | 2013-12-25 | 镇江万山红遍农业园 | 免疫增强剂及其使用方法 |
CN104147599A (zh) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | 一种疫苗佐剂、其制备方法及应用 |
-
2017
- 2017-07-21 CN CN201710598649.1A patent/CN107335055B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101690809A (zh) * | 2009-09-30 | 2010-04-07 | 西北农林科技大学 | 一种蜂胶与黄芪多糖复方纳米乳佐剂及其制备方法和应用 |
CN102524589A (zh) * | 2012-02-13 | 2012-07-04 | 天津市畜牧兽医研究所 | 一种断奶仔猪饲料及其制备方法与应用 |
CN103463634A (zh) * | 2013-09-09 | 2013-12-25 | 镇江万山红遍农业园 | 免疫增强剂及其使用方法 |
CN104147599A (zh) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | 一种疫苗佐剂、其制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
复方蜂胶纳米乳的制备及其品质评价;张旭 等;《西北农业学报》;20100525;第19卷(第5期);摘要,第24页左栏第1段至第27页右栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN107335055A (zh) | 2017-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wei et al. | Effects of Taishan Pinus massoniana pollen polysaccharide on immune response of rabbit haemorrhagic disease tissue inactivated vaccine and on production performance of Rex rabbits | |
EP3546570A2 (en) | Serum-free immune cell-culturing medium-added kit, method for culturing immune cells by using same kit, serum-free immune cell culture obtained by same kit or culturing method, and cosmetic composition comprising same culture | |
Gur et al. | In vitro and in vivo investigations of the wound healing effect of crude Spirulina extract and C-phycocyanin | |
CN108578688B (zh) | 多重纳米乳疫苗佐剂的制备方法 | |
Sun et al. | Effect of immunological enhancement of aloe polysaccharide on chickens immunized with Bordetella avium inactivated vaccine | |
CN109731002A (zh) | 造血干细胞动员剂及其应用 | |
Husni et al. | The effect of ethanol extract of moringa leaf (moringa oleifera lam) against the activity and capacity of phagocytosis of macrofag cells and the percentage of leukosit cells of white mice | |
CN103083510A (zh) | 一种提高禽免疫功能的中药口服液及其制备方法 | |
CN109207436A (zh) | 一株i群4型禽腺病毒毒株及其应用 | |
CN107335055B (zh) | 一种兽用中药免疫增强剂及其应用 | |
EP2120975A1 (de) | Vollblutkulturen mit stimulierten immunzellen und deren verwendung als heilmittel | |
CN106389477B (zh) | 一种土生戈登氏菌的全细胞植物油提取物的制备方法和应用 | |
Briggs et al. | Assessment of Immunostimulating effect of Carica papaya-based Immunostimulatory Complexes Against Streptococcus pneumoniae Infections. | |
CN103932179A (zh) | 一种缓解压力及护肝的保健食品及其二步发酵制备方法 | |
CN107708728A (zh) | 一种用于治疗胃癌的肿瘤疫苗及其制备方法 | |
Hasibuan et al. | The effect of herbal extracts and probiotic feeding on productivity and quality of broilers | |
CN112251402B (zh) | 蛋白肽、冻干粉、口服液及其制备方法 | |
CN117379470B (zh) | 一种复方免疫增强剂及其在水产养殖中的应用 | |
CN113940966B (zh) | 一种治疗大肠杆菌感染的裸花紫珠组合物及其制备方法和应用 | |
CN101559140A (zh) | 一种用于免疫调节的胶束溶液 | |
CA2437690A1 (en) | Ganoderma lucidum spores for treatment of autoimmune diseases | |
CN108379287A (zh) | 番荔枝多糖aspa80-1对小鼠巨噬细胞和树突状细胞免疫功能的影响及作用机制 | |
CN116268196B (zh) | 一种植物源复合添加剂及其应用 | |
WHITNEY | Hyperplasia of lymphoid tissue and lymphocytosis | |
Damayanti et al. | Immunostimulant Effect Test Of Curcuminoid Extract From Turmeric Rhizome (Curcuma Domestica Val.) In VCO On Rats Induced Cyclophosphamide Againts An Increasing Total Leukocytes And Leukocyte Differential |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A veterinary traditional Chinese medicine immunopotentiator and its application Effective date of registration: 20201009 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2020980006651 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211011 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2020980006651 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An animal traditional Chinese medicine immune enhancer and its application Effective date of registration: 20211013 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2021980010624 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2021980010624 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of veterinary traditional Chinese medicine immune enhancer and its application Effective date of registration: 20220916 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2022980015417 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230918 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2022980015417 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Kind of Animal Traditional Chinese Medicine Immunoenhancer and Its Application Effective date of registration: 20230921 Granted publication date: 20200501 Pledgee: Bank of China Limited by Share Ltd. Zhecheng branch Pledgor: SHANGQIU MEILAN BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2023980057629 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |